Lepton announces filing of a PCT application covering its proprietary breakthrough Castling Technology Lepton Pharmaceuticals announces that it has filed a PCT application with the US Patent Office entitled METHODS FOR ENHANCING THERAPEUTIC EFFICACY OF ISOLATED CELLS FOR CELL THERAPY. The Patent application covers Lepton’s breakthrough Castling technology, which is, in essence, the manipulation/engineering of...

Lepton and the Medical Center University of Freiburg sign a Sponsored Research Agreement to use miRNA Castling Technology to improve CAR T cells persistence and cytotoxicity for treatment of Cancer Lepton Pharmaceuticals announces that it signed a sponsored research agreement with the Institute for Transfusion Medicine and Gene Therapy (ITG), Medical Center – University of...

Lepton Pharmaceutical announces that on February 10, 2021 it entered into a Master Service Agreement with Axolabs GMBH, Kulmbach Germany. Pursuant to the agreement, Axolabs shall provide to Lepton Pharmaceutical chemical laboratory services for Lepton’s pipeline in development by directly targeting immunological drivers of diseases. Axolabs is a leading custom research organization providing high-end preclinical...